97 related articles for article (PubMed ID: 16571772)
21. Cancer gene therapy using in vivo electroporation of Flt3-ligand.
Shimao K; Takayama T; Enomoto K; Saito T; Nagai S; Miyazaki J; Ogawa K; Tahara H
Int J Oncol; 2005 Aug; 27(2):457-63. PubMed ID: 16010428
[TBL] [Abstract][Full Text] [Related]
22. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo.
Karsunky H; Merad M; Cozzio A; Weissman IL; Manz MG
J Exp Med; 2003 Jul; 198(2):305-13. PubMed ID: 12874263
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cells in germ-free and specific pathogen-free mice have similar phenotypes and in vitro antigen presenting function.
Walton KL; He J; Kelsall BL; Sartor RB; Fisher NC
Immunol Lett; 2006 Jan; 102(1):16-24. PubMed ID: 16105690
[TBL] [Abstract][Full Text] [Related]
24. Stroma-dependent development of two dendritic-like cell types with distinct antigen presenting capability.
Periasamy P; O'Neill HC
Exp Hematol; 2013 Mar; 41(3):281-92. PubMed ID: 23178375
[TBL] [Abstract][Full Text] [Related]
25. Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy.
Shaw SG; Maung AA; Steptoe RJ; Thomson AW; Vujanovic NL
J Immunol; 1998 Sep; 161(6):2817-24. PubMed ID: 9743341
[TBL] [Abstract][Full Text] [Related]
26. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses.
Yang AS; Lattime EC
Cancer Res; 2003 May; 63(9):2150-7. PubMed ID: 12727833
[TBL] [Abstract][Full Text] [Related]
27. Flt3 ligand antitumor activity in a murine breast cancer model: a comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action.
Braun SE; Chen K; Blazar BR; Orchard PJ; Sledge G; Robertson MJ; Broxmeyer HE; Cornetta K
Hum Gene Ther; 1999 Sep; 10(13):2141-51. PubMed ID: 10498246
[TBL] [Abstract][Full Text] [Related]
28. Immature dendritic cells (CD11c+ CD3- B220- cells) present in mouse peripheral blood.
Adachi Y; Toki J; Ikebukuro K; Tomita M; Kaneda H; Tanabe A; Jun L; Minamino K; Suzuki Y; Taketani S; Ikehara S
Immunobiology; 2002 Oct; 206(4):354-67. PubMed ID: 12437067
[TBL] [Abstract][Full Text] [Related]
29. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo.
Borges L; Miller RE; Jones J; Ariail K; Whitmore J; Fanslow W; Lynch DH
J Immunol; 1999 Aug; 163(3):1289-97. PubMed ID: 10415026
[TBL] [Abstract][Full Text] [Related]
30. Characterization of dendritic cells generated in vivo by an E. coli derived chimeric dual receptor agonist.
Kahn LE; Doshi PD; McGarity KL; Yu M; Bono CP; Lie WR; Rankin AM; Smidt ML; Streeter PR; Klein BK; Welply JK; Woulfe SL
Med Sci Monit; 2002 Dec; 8(12):BR504-14. PubMed ID: 12503028
[TBL] [Abstract][Full Text] [Related]
31. Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand.
Mosca PJ; Hobeika AC; Colling K; Clay TM; Thomas EK; Caron D; Lyerly HK; Morse MA
J Leukoc Biol; 2002 Sep; 72(3):546-53. PubMed ID: 12223523
[TBL] [Abstract][Full Text] [Related]
32. FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function.
Chen W; Chan AS; Dawson AJ; Liang X; Blazar BR; Miller JS
Biol Blood Marrow Transplant; 2005 Jan; 11(1):23-34. PubMed ID: 15625541
[TBL] [Abstract][Full Text] [Related]
33. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.
Fujii S; Shimizu K; Smith C; Bonifaz L; Steinman RM
J Exp Med; 2003 Jul; 198(2):267-79. PubMed ID: 12874260
[TBL] [Abstract][Full Text] [Related]
34. Flt3 Ligand Treatment Attenuates T Cell Dysfunction and Improves Survival in a Murine Model of Burn Wound Sepsis.
Patil NK; Bohannon JK; Luan L; Guo Y; Fensterheim B; Hernandez A; Wang J; Sherwood ER
Shock; 2017 Jan; 47(1):40-51. PubMed ID: 27454384
[TBL] [Abstract][Full Text] [Related]
35. Bovine NK cells acquire cytotoxic activity and produce IFN-gamma after stimulation by Mycobacterium bovis BCG- or Babesia bovis-exposed splenic dendritic cells.
Bastos RG; Johnson WC; Mwangi W; Brown WC; Goff WL
Vet Immunol Immunopathol; 2008 Aug; 124(3-4):302-12. PubMed ID: 18514329
[TBL] [Abstract][Full Text] [Related]
36. Treatment of hepatocellular carcinoma with adenoviral vector-mediated Flt3 ligand gene therapy.
Wang H; Dai J; Hou S; Qian W; Li B; Ma J; Fan X; Zhao J; Yang S; Sang H; Yang Q; Wang R; Guo Y
Cancer Gene Ther; 2005 Sep; 12(9):769-77. PubMed ID: 15877081
[TBL] [Abstract][Full Text] [Related]
37. Dendritic cell homeostasis is maintained by nonhematopoietic and T-cell-produced Flt3-ligand in steady state and during immune responses.
Saito Y; Boddupalli CS; Borsotti C; Manz MG
Eur J Immunol; 2013 Jun; 43(6):1651-8. PubMed ID: 23519969
[TBL] [Abstract][Full Text] [Related]
38. CD8alpha(-) and CD8alpha(+) subclasses of dendritic cells undergo phenotypic and functional maturation in vitro and in vivo.
De Smedt T; Butz E; Smith J; Maldonado-López R; Pajak B; Moser M; Maliszewski C
J Leukoc Biol; 2001 Jun; 69(6):951-8. PubMed ID: 11404381
[TBL] [Abstract][Full Text] [Related]
39. Role of marginal zone B lymphocytes in invariant NKT cell activation.
Bialecki E; Paget C; Fontaine J; Capron M; Trottein F; Faveeuw C
J Immunol; 2009 May; 182(10):6105-13. PubMed ID: 19414762
[TBL] [Abstract][Full Text] [Related]
40. Thymic but not splenic CD8⁺ DCs can efficiently cross-prime T cells in the absence of licensing factors.
Dresch C; Ackermann M; Vogt B; de Andrade Pereira B; Shortman K; Fraefel C
Eur J Immunol; 2011 Sep; 41(9):2544-55. PubMed ID: 21748731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
